Sign up to save your podcasts
Or
Share FDA approves second Alzheimer’s treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA approves second Alzheimer’s treatment
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By POLITICO
4.7
453453 ratings
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like POLITICO's Pulse Check
View all
POLITICO's Off Message
610 Listeners
The Conversation with Dasha Burns
1,514 Listeners
The Playbook Podcast
691 Listeners
The Daily
112,049 Listeners
Power Play
963 Listeners
Women Rule
308 Listeners
Up First from NPR
56,516 Listeners
EU Confidential
105 Listeners
What the Health? From KFF Health News
493 Listeners
POLITICO Money
206 Listeners
FT News Briefing
645 Listeners
Fiction - Comedy Fiction
6,445 Listeners
POLITICO Energy
141 Listeners
POLITICO Tech
390 Listeners
Westminster Insider
39 Listeners
POLITICO Berlin Playbook
11 Listeners
The Headlines
613 Listeners